After-Hours Stock Movers 02/06: (ASRT) (PINS) (UBER) Higher; (ZGNX) (MYGN) (RESN) Lower (more...)
After-Hours Stock Movers
Assertio Therapeutics, Inc. (NASDAQ: ASRT) 51% HIGHER; entered into a definitive agreement (Agreement) with Collegium Pharmaceutical, Inc. (Nasdaq: COLL) pursuant to which Collegium will acquire the NUCYNTA® franchise of products from the Company. The closing of the agreement is expected by February 14, 2020.
Zogenix, Inc. (NASDAQ: ZGNX) 33% LOWER; reported positive top-line results from its global Phase 3 clinical trial (Study 1601) of its lead investigational therapy, FINTEPLA® (ZX008, fenfluramine oral solution) in Lennox-Gastaut Syndrome (LGS), a severe and treatment-resistant childhood-onset epilepsy. The trial met its primary objective of demonstrating that FINTEPLA at a dose of 0.7 mg/kg/day was superior to placebo in reducing the frequency of drop seizures, based on the change between baseline and the titration and maintenance treatment period (p=0.0012). The same dose of FINTEPLA (0.7 mg/kg/day) also demonstrated statistically significant improvements versus placebo in key secondary efficacy measures, including the proportion of patients with a clinically meaningful reduction (50%) in drop seizure frequency. A decrease in the frequency of drop seizures between baseline and the treatment period was observed for a lower dose of FINTEPLA (0.2 mg/kg/day) compared to placebo, but this change did not reach statistical significance (p=0.0915). FINTEPLA was generally well-tolerated, with the adverse events consistent with those observed in the Companys two prior Phase 3 studies in Dravet syndrome.
Myriad Genetics, Inc. (NASDAQ: MYGN) 30.3% LOWER; announced today that R. Bryan Riggsbee, Chief Financial Officer, has been appointed Interim President and CEO effective immediately and will also continue to serve as Chief Financial Officer. Mark C. Capone has resigned as President and Chief Executive Officer and as a member of the Companys Board of Directors, effective immediately. Mr. Capone will remain available to the Company to assist in this transition.
TeleNav (NASDAQ: TNAV) 27.2% HIGHER; reported Q2 EPS of $0.13, $0.21 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $67.3 million versus the consensus estimate of $56.14 million.
Resonant Inc. (NASDAQ: RESN) 17.7% LOWER; announced that it is offering to sell shares of its common stock in an underwritten public offering. Resonant intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Pinterest (NYSE: PINS) 16.9% HIGHER; reported Q4 EPS of ($0.06), $0.14 worse than the analyst estimate of $0.08. Revenue for the quarter came in at $400 million versus the consensus estimate of $371.23 million. Global Monthly Active Users (MAUs) grew 26% year over year to 335 million. Pinterest sees FY2020 revenue of $1.52 billion, versus the consensus of $1.5 billion.
Synaptics (NASDAQ: SYNA) 15% HIGHER; reported Q2 EPS of $2.04, $0.59 better than the analyst estimate of $1.45. Revenue for the quarter came in at $388.3 million versus the consensus estimate of $354.91 million. Synaptics sees Q3 2020 revenue of $330-350 million, versus the consensus of $299.03 million.
Manitowoc (NYSE: MTW) 13.4% LOWER; reported Q4 EPS of $0.35, $0.06 better than the analyst estimate of $0.29. Revenue for the quarter came in at $463.4 million versus the consensus estimate of $493.27 million. Manitowoc sees FY2020 revenue of $1.6-1.7 billion, versus the consensus of $1.73 billion.
Skechers USA (NYSE: SKX) 11.4% HIGHER; reported Q4 EPS of $0.39, in-line with the analyst estimate of $0.39. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.25 billion.
2u (NASDAQ: TWOU) 9% HIGHER; reported Q4 EPS of ($0.18), in-line with the analyst estimate of ($0.18). Revenue for the quarter came in at $163.2 million versus the consensus estimate of $161.38 million. 2u sees Q1 2020 revenue of $170-180 million, versus the consensus of $172.45 million. 2u sees FY2020 revenue of $725-750 million, versus the consensus of $729.39 million.
Take-Two Interactive Software (NASDAQ: TTWO) 8.3% LOWER; reported Q3 GAAP EPS of $1.43, which may not compare to the analyst estimate of $1.75. Revenue for the quarter came in at $930.1 million versus the consensus estimate of $922.12 million. Take-Two Interactive Software sees Q4 2020 GAAP EPS of $0.92-$1.12, versus the consensus of $0.92. Take-Two Interactive Software sees Q4 2020 revenue of $635-685 million, versus the consensus of $560.44 million.
eBay (Nasdsaq: EBAY) 6.6% LOWER; Intercontinental Exchange, Inc. (NYSE: ICE), a leading operator of global exchanges and clearing houses and provider of data and listings services, is sharing the following statement: Based on investor conversations following today’s ICE earnings call, ICE has decided to cease exploring strategic opportunities with eBay (Nasdsaq: EBAY).
Teradata Corp. (NYSE: TDC) 6.4% LOWER; reported Q4 EPS of $0.22, $0.06 better than the analyst estimate of $0.16. Revenue for the quarter came in at $494 million versus the consensus estimate of $474.6 million. Teradata Corp. sees Q1 2020 EPS of $0.22-$0.24, versus the consensus of $0.30. Teradata Corp. sees FY2020 EPS of $1.18-$1.22, versus the consensus of $1.47.
NortonLifeLock Inc. (NASDAQ: NLOK) 5.9% HIGHER; reported Q3 EPS of $0.25, $0.17 better than the analyst estimate of $0.08. Revenue for the quarter came in at $618 million versus the consensus estimate of $607.97 million. NortonLifeLock Inc. sees Q4 2020 EPS of $0.15-$0.20, versus the consensus of $0.06. NortonLifeLock Inc. sees Q4 2020 revenue of $595-605 million, versus the consensus of $608.73 million.
Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) 5.3% LOWER; announced that it plans to offer and sell shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Corbus. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
ADMA Biologics, Inc. (Nasdaq: ADMA) 5% LOWER; announced that it has commenced an $75 million underwritten public offering of its common stock. The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Uber (NYSE: UBER) 5% HIGHER; reported Q4 EPS of ($0.64), $0.03 better than the analyst estimate of ($0.67). Revenue for the quarter came in at $4.07 billion versus the consensus estimate of $4.06 billion.
DXC Technology (NYSE: DXC) 4.2% HIGHER; reported Q3 EPS of $1.25, $0.16 better than the analyst estimate of $1.09. Revenue for the quarter came in at $5.02 billion versus the consensus estimate of $4.9 billion.